Pulmonx (LUNG) Research & Development (2019 - 2025)

Pulmonx (LUNG) has reported Research & Development for 7 consecutive years, with $4.8 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Research & Development rose 29.43% year-over-year to $4.8 million in Q3 2025; TTM through Sep 2025 was $18.9 million, a 8.27% increase from a year earlier, with the FY2024 full-year figure at $17.6 million, down 2.82% from the prior year.
• Research & Development was $4.8 million for Q3 2025 at Pulmonx, down from $5.3 million in the prior quarter.
• Over five years, Research & Development peaked at $5.7 million in Q2 2023 and troughed at $2.8 million in Q3 2021.
• A 5-year average of $4.2 million and a median of $4.0 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 145.86% in 2021 and retreated 11.28% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $3.7 million in 2021, then grew by 5.26% to $3.9 million in 2022, then declined by 0.18% to $3.9 million in 2023, then grew by 2.7% to $4.0 million in 2024, then gained by 21.12% to $4.8 million in 2025.
• The last three Research & Development figures came in at $4.8 million (Q3 2025), $5.3 million (Q2 2025), and $4.8 million (Q1 2025), per Business Quant data.